Global Antifungals Market Report 2020: Market was Valued at $9.4 Billion in 2018 and is Expected to Grow to $11.96 Billion through 2022 - ResearchAndMarkets.com

DUBLIN--()--The "Antifungals Global Market Report 2020" report has been added to ResearchAndMarkets.com's offering.

The global antifungals market was valued at about $9.4 billion in 2018 and is expected to grow to $11.96 billion at a CAGR of 6.2% through 2022.

The antifungals market consists of sales of antifungal drugs which are used to detect and eliminate fungal pathogens. The fungal pathogens thrive in the body under unhygienic and unclean environments. These drugs are also known as an antimycotic medication, used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis (thrush), serious systemic infections such as cryptococcal meningitis, and others.

North America was the largest region in the antifungals in 2018, followed by Europe and Asia Pacific respectively. This region is expected to remain the largest during the next five years. The antifungals in Asia Pacific is forecasted to register the highest CAGR during 2018-2023.

A point prevalence survey was conducted in Turkey, in 2018. According to the survey, antifungal drugs were mostly prescribed in pediatric hematology and oncology (PHO) units (35.2%), followed by neonatal ICUs (NICUs) (19.6%). The other units prescribing antifungal drugs included pediatric services (18.3%), pediatric ICUs (PICUs) (14.6%) and hematopoietic (HSCT) units (7.3%).

According to the same survey, the antifungals were used for prophylaxis in 48.8% of patients and about 50% of patients were treated with antifungal drugs based on observation. Among 50% of patients, who were treated post observation, around 18.8% of patients were prescribed an antifungal therapy and 31.2% of patients were targeted for the treatments.

Antifungal drugs manufacturers are offering skimming price for branded drugs. The discovery, development and manufacturing processes of branded drugs generally require high investments. As a result, companies in the market offer the branded drugs at the highest initial prices, and implement other pricing strategies to ensure the product stays competitive at a high price. Price skimming is a pricing strategy in which a company charges a high initial price and then gradually lowers the price to attract more price-sensitive customers. It is used to maximize profits when a new product is introduced in the market. Manufacturers and marketers of branded drugs should consider adopting the price skimming strategy for branded drugs. They should price these branded drugs high to recover the high costs incurred during drug development and manufacturing.

Drug developers and manufacturers are scaling up the various departments such as research and development, marketing, and manufacturing through collaborations and strategic partnerships with other companies and research institutes, to expand the product portfolios. So, companies in the anti-infective drugs market should consider strategic collaborations to broaden their scope and product portfolios to increase the revenues and stay competitive in the market.

Major players in the market are Pfizer, Novartis, Merck & Co., Bayer Healthcare and Abbott Laboratories.

Scope

  • Markets Covered: 1) By Drug Type: Echinocandins, Azoles, Polyenes, Allylamines 2) End users: Hospitals & Clinics, Dermatology clinics, Other Users 3) By Route of Administration: Oral, Parenteral, Topical 4) By Therapeutic Indications: Aspergillosis, Dermatophytosis, Candidiasis, Others
  • Companies Mentioned: Pfizer, Novartis, Merck & Co., Bayer Healthcare, Abbott Laboratories
  • Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA
  • Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
  • Time Series: Five years historic and forecast.
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Companies Mentioned

  • Pfizer
  • Novartis
  • Merck & Co.
  • Bayer Healthcare
  • Abbott Laboratories
  • Sanofi-Aventis
  • Kramer Laboratories
  • Glaxosmithkline Gilead
  • Enzon Pharmaceuticals Inc.
  • Basilea Pharmaceutica AG
  • PerkinElmer
  • Alternaria
  • Sigma-Aldrich
  • Astellas Pharma Inc.
  • Janssen Pharmaceutica NV
  • Zydus Cadila Healthcare Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Sumitomo Dainippon Pharma Co. Ltd.
  • Scynexis Inc.
  • Mayne Pharma Inc.
  • Cosmo Pharmaceuticals NV

For more information about this report visit https://www.researchandmarkets.com/r/4rtfsq

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900